Literature DB >> 8226480

Exercise and glucocorticoid-induced diaphragmatic myopathy.

F K Lieu1, S K Powers, R A Herb, D Criswell, D Martin, C Wood, W Stainsby, C L Chen.   

Abstract

We tested the hypothesis that a chronically active muscle, such as the rat diaphragm, would be more resistant to glucocorticoid-induced myopathy than a less active locomotor skeletal muscle (plantaris). Furthermore, we sought to determine whether endurance exercise could antagonize the glucocorticoid-induced atrophy in the diaphragm. Rats were assigned to one of seven experimental groups (n = 10 per group) and injected daily over a 10-day period with either a sham solution or prednisolone acetate: group 1: control; sedentary and sham injected; group 2: control; exercise trained and sham injected; group 3; sedentary; prednisolone (0.5 mg.kg-1 x day-1); group 4: sedentary; prednisolone (1.0 mg.kg-1 x day-1); group 5: sedentary; prednisolone (2.0 mg.kg-1 x day-1); group 6: sedentary; prednisolone (5.0 mg.kg-1 x day-1); group 7: exercise trained; prednisolone (5.0 mg.kg-1 x day-1). Slope differences in the dose-response curves suggest that prednisolone-induced muscle atrophy in the plantaris was more severe than that in the diaphragm. Furthermore, high doses of prednisolone resulted in a differential effect on muscle bioenergetic enzyme activities in the plantaris and diaphragm. Prednisolone treatment (> or = 2 mg.kg-1 x day-1) resulted in a significant reduction in phosphofructokinase activity (expressed as microM substrate.min-1 x mg protein-1) and an increase in 3-hydroxyacyl-CoA dehydrogenase activity in the plantaris muscle. In contrast, prednisolone treatment did not influence phosphofructokinase activity (P > 0.05) in the diaphragm but decreased (P < 0.05) relative citrate synthase activity. Finally, 90 min daily of endurance exercise did not antagonize prednisolone-induced myopathy in either the diaphragm or the plantaris.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8226480     DOI: 10.1152/jappl.1993.75.2.763

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  7 in total

Review 1.  Respiratory muscle fibres: specialisation and plasticity.

Authors:  B Polla; G D'Antona; R Bottinelli; C Reggiani
Journal:  Thorax       Date:  2004-09       Impact factor: 9.139

Review 2.  Steroid myopathy: some unresolved issues.

Authors:  M A Minetto; F Lanfranco; G Motta; S Allasia; E Arvat; G D'Antona
Journal:  J Endocrinol Invest       Date:  2011-05       Impact factor: 4.256

3.  Effects of eldecalcitol on bone and skeletal muscles in glucocorticoid-treated rats.

Authors:  Hayato Kinoshita; Naohisa Miyakoshi; Yuji Kasukawa; Sadaoki Sakai; Ayako Shiraishi; Toyohito Segawa; Kentaro Ohuchi; Masashi Fujii; Chie Sato; Yoichi Shimada
Journal:  J Bone Miner Metab       Date:  2015-05-06       Impact factor: 2.626

4.  Mineralocorticoid receptor antagonists improve membrane integrity independent of muscle force in muscular dystrophy.

Authors:  J Spencer Hauck; Jeovanna Lowe; Neha Rastogi; Kevin E McElhanon; Jennifer M Petrosino; Kyra K Peczkowski; Ashlee N Chadwick; Jonathan G Zins; Federica Accornero; Paul M L Janssen; Noah L Weisleder; Jill A Rafael-Fortney
Journal:  Hum Mol Genet       Date:  2019-06-15       Impact factor: 6.150

5.  Regulation of type IV collagen gene expression and degradation in fast and slow muscles during dexamethasone treatment and exercise.

Authors:  A M Ahtikoski; E-M Riso; S O A Koskinen; J Risteli; T E S Takala
Journal:  Pflugers Arch       Date:  2003-12-18       Impact factor: 3.657

Review 6.  Prolonged mechanical ventilation alters diaphragmatic structure and function.

Authors:  Scott K Powers; Andreas N Kavazis; Sanford Levine
Journal:  Crit Care Med       Date:  2009-10       Impact factor: 7.598

7.  The effect of high glucocorticoid administration and food restriction on rodent skeletal muscle mitochondrial function and protein metabolism.

Authors:  Y Nancy You; Kevin R Short; Marion Jourdan; Katherine A Klaus; Stephane Walrand; K Sreekumaran Nair
Journal:  PLoS One       Date:  2009-04-20       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.